- MACD is crossing MACD signal line at 0.1. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Marinus (MRNS) gets positive FDA response for phase III Marigold study on oral ganaxolone in children and young adults with CDKL5 deficiency disorder that appears sufficient to support the NDA filing.
Marinus received a positive response from the FDA on sufficiency of Marigold Study data to support filing of NDA for the use of ganaxolone in CDD.
Marinus management will participate in the 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect 2021 Conference.
Here we discuss five biotech stocks - EDIT, VRTX, NTLA, CBAY, MRNS - that could prove to be great investments in the long run.
Marinus Pharmaceuticals announced it has been selected for inclusion in the Nasdaq Biotechnology Index (NBI).
Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of September. At Insider Monkey, we follow nearly 817 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are […]
On Tuesday, shares of up-and-coming biotechs Marinus Pharmaceuticals (NASDAQ: MRNS), iBio (NYSEMKT: IBIO), and Arcturus Therapeutics Holdings (NASDAQ: ARCT) fell by 12%, 13%, and 19%, respectively. Arcturus is a bit more of a mystery. Marinus' ganaxolone pipeline epilepsy drug has tested well, and iBio and Marinus remain intriguing underdog coronavirus vaccine plays.
Marinus Pharmaceuticals announces the pricing of an underwritten public offering of 5 million shares of its common stock for gross proceeds of $70MM.